The claim worth examining
The longevity market trains people to equate biological plausibility with a purchase decision. GlyNAC supports glutathione synthesis. NMN raises NAD-related metabolites. Spermidine is linked to autophagy. Each sentence can be true while the implied conclusion—this will materially extend my healthy life—remains unproven.
The practical error is not curiosity. It is adding interventions faster than you can measure, attribute, or safely stop them.
What the human evidence actually says
GlyNAC is a useful case study in uncertainty. A small randomized trial in 24 older adults reported improvements across multiple intermediate and functional outcomes. A separate randomized trial in 114 healthy older adults did not improve its primary glutathione endpoints overall. The honest conclusion is promising but unresolved—not proven and not worthless.
NMN has several short randomized trials and reliably raises NAD-related metabolites. But a 2024 meta-analysis of eight randomized trials found no significant pooled improvement in the major glucose-control and lipid outcomes it assessed. Spermidine's larger 12-month cognition trial also missed its primary endpoint.
The decision rule
Do not add a supplement until you can write one sentence for each of five questions: What is the target? What is the relevant human evidence? What is the baseline? How will safety and interactions be reviewed? What result or side effect makes you stop?
When one of those answers is blank, the next action is not a product comparison. It is closing the decision gap.
The seven-day protocol
This week is a stack audit, not a stack expansion. The goal is to turn accumulated products into explicit experiments.
- List every supplement, dose, recurring cost, and the person or claim that caused you to start it.
- Assign one specific target to each product. 'Longevity,' 'inflammation,' and 'optimization' are not specific enough.
- Mark the best evidence as human outcome, human intermediate marker, observational, mechanistic, or animal-only.
- Identify interactions, duplicate ingredients, pregnancy or surgery considerations, and conditions that deserve a pharmacist or clinician review.
- Write a measurement window and a stop rule.
- Remove or pause one product that has no defensible target or evaluation plan, unless a qualified clinician prescribed it.
The metric to track
Track the percentage of your stack with a written target, safety review, measurement window, and stop rule. The useful target is 100%. A smaller stack with complete decision logic is more sophisticated than a larger stack with prettier mechanisms.